Novabay introduces a new class of agonacides with NVC422

NovaBay Pharmaceuticals, Inc., based in Emeryville, CA, is innovating a new class of drugs, known as Aganocide compounds, that mimic the body's natural defense against infection. The Aganocides could potentially equal or exceed the utility of antibiotics and address the problem of antibiotic resistance via their novel mechanism. A poster relating to a study of NVC422, was presented at the Infectious Diseases Society of America meeting and was titled "A Pilot Study to Evaluate the Safety and Efficacy of NVC-422 Topical Gel in Impetigo, Including MRSA". from the research team led by Ken Krantz MD, PhD of NovaBay which focused on impetigo, a highly contagious skin infection that affects mostly children and is caused by S. aureus, including the increasingly common antibiotic-resistant MRSA and S. pyogenes. It is currently treated with antibiotic ointments to which bacteria may develop resistance.